Multi-center Clinical Study on Neonatal Hyperbilirubinemia

October 29, 2021 updated by: Zhangbin Yu, Nanjing Medical University

Multi-center Clinical Study on Early Screening and Treatment of Hyperbilirubinemia of Term and Late-preterm Neonates

Eight hospitals in China will participate in the study, which aims to decrease the incidence of severe hyperbilirubinemia.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Through a prospective cohort study of healthy term and near-term infants, the study tries to truly reflect the epidemiology, intervention status, and outcomes of neonatal hyperbilirubinemia and the cost. Hopefully, by improving the quality of management of neonatal jaundice,we can explore and obtain a healthy term and near-term jaundice management model suitable for China's national condition, which can eventually reduce the incidence rate of neonatal severe hyperbilirubinemia and bilirubin encephalopathy.

Study Type

Interventional

Enrollment (Actual)

20000

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Jiangsu
      • Nanjing, Jiangsu, China, 210000
        • Nanjing Maternity and Child Health Care Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 day to 4 weeks (CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

term or near-term neonates with gestational age ≥35w and birth weight ≥2000g.

Exclusion Criteria:

Infants admitted to a higher level of intervention before discharge.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: HEALTH_SERVICES_RESEARCH
  • Allocation: NON_RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
NO_INTERVENTION: Before-intervention phase
All the healthy infants who were admitted from March 2018 to August 2018 to the Well Baby nurse of different hospitals.
EXPERIMENTAL: Intervention phase
All the healthy infants who were admitted from September 2018 to February 2019 to the Well Baby nurse of different hospitals.During this phase,multiple intervention bundles of quality improvement will be implemented.
During the Intervention phase and Sustainability phase ,The hospitals will receive training of multiple evidence based quality improvement methods.
EXPERIMENTAL: Sustainability intervention phase
All the healthy infants who were admitted from March 2019 to August 2019 to the Well Baby nurse of different hospitals.In the Sustainability intervention phase,multiple intervention bundles of quality improvement will be continuous implemented.
During the Intervention phase and Sustainability phase ,The hospitals will receive training of multiple evidence based quality improvement methods.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The incidence of bilirubin encephalopathy
Time Frame: 18 months
18 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The incidence of severe hyperbilirubinemia
Time Frame: 18 months
Severe hyperbilirubinemia:total serum bilirubin more than 20mg/dL
18 months
The rate of lost to follow-up
Time Frame: 18 months
The rate of lost to follow-up for jaundice after discharge from well-baby nursery
18 months
The incidence of adverse neurological outcomes in patients with severe hyperbilirubinemia
Time Frame: 42 months
Patients with severe hyperbilirubinemia from 11 hospitals will be followed to investigate their neurological outcomes until 24 months after birth
42 months
Medical costs in patients with severe hyperbilirubinemia
Time Frame: 18 months
To compare the medical costs in patients with severe hyperbilirubinemia from 3 phases of quality improvement.
18 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Zhiyong Sun, PHD, JiLin Women and Children Health Hospital
  • Principal Investigator: Haiyan Cai, PHD, Qinhuangdao Maternal and Child Health Care Hospital
  • Principal Investigator: Yonghui Yu, MD, Shandong Provincial Hospital
  • Principal Investigator: Xin Yuan, MD, Shan Dong Qian Fo Shan Hospital
  • Principal Investigator: Jin Qian, MD, Shan Dong Liao Cheng Hospital
  • Principal Investigator: Wenyan Tang, PHD, Jiangxi Maternal and Child Health Hospital
  • Principal Investigator: Zhankui Li, PHD, Northwest Women's and Children's Hospital, Xi'an, Shaanxi
  • Principal Investigator: Jie Gu, PHD, Yin Chuan Maternity and Child Health Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

March 1, 2018

Primary Completion (ACTUAL)

August 31, 2021

Study Completion (ACTUAL)

October 15, 2021

Study Registration Dates

First Submitted

January 30, 2019

First Submitted That Met QC Criteria

January 30, 2019

First Posted (ACTUAL)

January 31, 2019

Study Record Updates

Last Update Posted (ACTUAL)

November 1, 2021

Last Update Submitted That Met QC Criteria

October 29, 2021

Last Verified

October 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • NMU-FY2018-72

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.